In this episode released just in time for the holidays, Anthony and Bernie are joined by Tycel Phillips, MD to discuss the most exciting updates from ASH 2024 in lymphoma! Pour yourself a drink and have a listen!

Some selected abstracts:

• EA4151: https://ash.confex.com/ash/2024/webprogram/Paper212973.html
• Triangle Updates: https://ash.confex.com/ash/2024/webprogram/Paper200735.html , https://ash.confex.com/ash/2024/webprogram/Paper201441.html
• EA4181: https://ash.confex.com/ash/2024/webprogram/Paper194641.html
• ENRICH: https://ash.confex.com/ash/2024/webprogram/Paper199710.html
• inMIND: https://ash.confex.com/ash/2024/webprogram/Paper212970.html
• POLARIX Long-Term F/U: https://ash.confex.com/ash/2024/webprogram/Paper197938.html

In this episode, Anthony and Bernie are joined by Dr. Aaron "Papa Heme" Goodman and Dr. Manni "Myeloma Man" Mohyuddin to discuss the most intriguing ASH 2024 abstracts! Should any of the research from ASH 2024 change your practice? Find out!

In this episode, Bernie and Anthony are joined by two special guest expert hematologists:

Dr. David Russler-Germain

Dr. Tycel Phillips

We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?

Stay tuned to find out!

In this episode, Tycel Phillips, MD joins Anthony and Bernie to discuss updates in Mantle Cell Lymphoma, including the TRIANGLE study and the recently published results of glofitamab in R/R MCL.

TRIANGLE: https://pubmed.ncbi.nlm.nih.gov/38705160/

Glofitamab: https://pubmed.ncbi.nlm.nih.gov/39365960/

In this episode, Anthony and Bernie discuss the recently reported APOLLO trial in high-risk APL and debate whether this should represent the new standard of care in this population. We also review key practical considerations for the treatment of APL patients, including side effect management and treatment of APL in unique clinical scenarios.

APOLLO: https://library.ehaweb.org/eha/2024/eha2024-congress/422206/uwe.platzbecker.first.results.of.the.apollo.trial.a.randomized.phase.iii.study.html

In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024!

How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today?

And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!

In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!

Abstracts discussed:

• https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
• https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
• https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
• https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
• https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
• https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
• https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
• https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)